Upcoming inter-discplinary science conferences
April 4, 2011 § Leave a comment
Networking online through sites like iAMscientist is great, but it’s also great to network in person as well. One of the best places to network in person is at a conference, where the movers and shakers of the field come together to discuss new ideas, to present their work, and to have a good time. Here are just a few events coming up where there’s still time to register and to make plans to attend. More conferences taking place in the United States and around the world can be found at Science Events.
TEDxMileHigh: April 7, 2011 in Denver, Colorado
An independently organized TED event, TEDxMileHigh will feature presentations from over 20 leaders in the Colorado area. We’ve featured TED talks before here on the blog, but here’s a chance to hear some of those “ideas worth spreading” live.
TEDxMileHigh is committed to showcasing new and powerful ideas and inspiring the community into action to help shape the future of the Mile High community and beyond. The event will bring together a diverse group of thought leaders and innovators to educate, inspire, and stimulate change.
The Future of Biosimilars in the US: Legal, Regulatory, Scientific, Clinical, and Payer Issues: May 4-5, 2011 in Bethesda, Maryland.
The first comprehensive conference on biosimilars since the enactment of BPCIA, the Future of Biosimilars Conference is geared toward industry professional in biomedicine, clinical safety, health care, and law. Some of the questions to be addressed include:
• What level of similarity and extent of physio-chemical and biological data will be required to demonstrate the follow-on protein to be “highly similar” to the innovator product and to qualify as a biosimilar?
• What is the value of non-clinical testing for the demonstration of “biosimilarity”?
• How extensive should clinical testing be?
• To what extent can one extrapolate findings from one population to other populations based on the originator’s data?
• What criteria must be fulfilled to achieve interchangeability status?
• How does exclusivity operate under the BPCIA? Is it market or data exclusivity?
• When can supplemental applications qualify for exclusivity?
• What are the implications for intellectual property protection and litigation?
• What labelling and nomenclature need to be applied to biosimilars?
• What will be the impact on patient access to expensive biological medicines and to what extent will patient choice become compromised or even severely limited?
On March 23, 2010, the Biologics Price Competition and Innovation Act was enacted into law as part of U.S. healthcare reform, establishing an approval pathway for biosimilar biological products in the US. This Act and the way it is implemented will have huge impact on the development and availability of biological medicines in the US, both from an intellectual property and market access perspective. Hear the perspectives of FDA, industry, lawyers, academics, clinicians, payers and patients on the introduction of biosimilars to the US, including the critical challenges and the current ideas of these stakeholders.
Compass Summit: October 24-26, 2011 at the Terranea Resort near Los Angeles, CA
A brand new summit tasked to take an interdisciplinary look at science, technological, and social innovation and its ramifications on society, Compass Summit has partnered with Scientific American, Fenton, and the 100 People Foundation to put together this summit of influential thinkers in order to come up with inter-disciplinary solutions to the world’s problems.
The topics Compass Summit will address include:
* the future of money
* robots and job creation
* the waning of the precautionary principle in applied science
* capital for the biggest building boom in world history
* the new silk roads of world trade
* the need for a new green revolution and new sources of fresh water
Compass Summit is by invitation only and attendance is restricted to 300 participants. These will include thought leaders from across industry, science and government, senior executives, and venture capitalists. For application information, please e-mail firstname.lastname@example.org. The registration fee is US$4,000; participants who can afford to do so are asked to help subsidize those for whom the fee would represent a hardship.